Epirus, Chemo Group deal

Epirus granted Chemo’s mAbxience subsidiary rights to commercialize BOW015 in Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela. BOW015 is a biosimilar version of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). Chemo will be responsible for regulatory submissions and commercialization. Chemo and Epirus will split revenue 60/40, with Epirus supplying the product to mAbxience. BOW015 launched in India in November 2014 under a partnership Ranbaxy Laboratories Ltd., which Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) acquired (see BioCentury, Jan. 13, 2014). ...